SD-169

• Description :

  SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  P38 MAPK

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/sd-169.html

• Purity :

  99.44

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC2=C(NC=C2)C=C1)N

• Molecular Formula :

  C9H8N2O

• Molecular Weight :

  160.18

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318 (1) :99-107.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  P38α; p38β

• CAS Number :

  [1670-87-7]